Radius Health, Inc. (RDUS)

56.33
0.25 0.45
NASDAQ
Prev Close 56.08
Open 55.87
Day Low/High 55.59 / 57.11
52 Wk Low/High 24.75 / 79.90
Volume 157.95K
Exchange NASDAQ
Shares Outstanding 43.08B
Market Cap 2.44B
Div & Yield N.A. (N.A)

Latest News

Short Interest Increases 11.4% For RDUS

Short Interest Increases 11.4% For RDUS

The most recent short interest data has been released for the 08/31/2016 settlement date, which shows a 739,137 share increase in total short interest for Radius Health Inc , to 7,245,291, an increase of 11.36% since 08/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

These 5 Stocks Are Poised for Big Breakouts

These 5 Stocks Are Poised for Big Breakouts

Here's a technical look at how to trade five stocks within range of triggering big breakouts.

Radius Health Announces Three Presentations On RAD1901 At The San Antonio Breast Cancer Symposium (SABCS) December 6-10, 2016

Radius Health Announces Three Presentations On RAD1901 At The San Antonio Breast Cancer Symposium (SABCS) December 6-10, 2016

SABCS to include three abstracts from the development program for RAD1901 as a potential treatment of ER-positive advanced breast cancer

JAMA Publishes Positive Phase 3 Data For Abaloparatide In Postmenopausal Women With Osteoporosis

JAMA Publishes Positive Phase 3 Data For Abaloparatide In Postmenopausal Women With Osteoporosis

Results from Phase 3 ACTIVE trial show abaloparatide significantly reduced the incidence of new vertebral fractures and nonvertebral fractures in postmenopausal women with osteoporosis at 18 months when compared with placebo

Overboarded Directors at Valeant, Yahoo! and Elsewhere Struggle With Activists, M&A

Overboarded Directors at Valeant, Yahoo! and Elsewhere Struggle With Activists, M&A

Board members who sit on four or more boards may find it impossible to manage their time when faced with an insurgent investor or merger situation -- or both.

Radius Health, Subject of Takeover Talk, Rises Again

Radius Health, Subject of Takeover Talk, Rises Again

The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.

Radius Health Announces Multiple Presentations At The American Society For Bone And Mineral Research 2016 Annual Meeting September 16-19, 2016

Radius Health Announces Multiple Presentations At The American Society For Bone And Mineral Research 2016 Annual Meeting September 16-19, 2016

ASBMR Meeting to include an oral late-breaking presentation of the results of the clinical development of an optimized abaloparatide transdermal patch

'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone

'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone

Cramer says don't buy Tesaro but do buy Cirrus Logic.

Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?

Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?

Cramer says discipline is needed to start trimming positions and taking profits.

5 Best-Positioned Biotech Stocks on Brexit Volatility

5 Best-Positioned Biotech Stocks on Brexit Volatility

Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.

Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting

Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting

- Data demonstrate that abaloparatide-SC reduced the risk of osteoporotic fractures and increased bone mineral density across a broad group of postmenopausal women with osteoporosis regardless of baseline characteristics -

Jim Cramer's Top Takeaways: Radius Health, Seres Therapeutics

Jim Cramer's Top Takeaways: Radius Health, Seres Therapeutics

Radius Health and Seres Therapeutics have something in common, Cramer says -- both are great biotechs being dragged down by the current market.

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says

'Mad Money' Lightning Round: I'm a Palo Alto Networks Guy

'Mad Money' Lightning Round: I'm a Palo Alto Networks Guy

Cramer loves Bristol-Myers and he's not betting against Goldman Sachs.